Trexquant Investment’s 4D Molecular Therapeutics FDMT Stock Holding History

Trexquant Investment’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-13,229	Closed	-$99.2K	–	1842
2025 Q4	$99.2K	Sell	13,229 -68,125	-84%	-$691K	﹤0.01%	1547
2025 Q3	$707K	Buy	+81,354	New	+$486K	0.01%	1244
2024 Q3	–	Sell	-28,385	Closed	-$596K	–	1627
2024 Q2	$596K	Buy	+28,385	New	+$712K	0.01%	1188
2023 Q4	–	Sell	-44,443	Closed	-$566K	–	1536
2023 Q3	$566K	Buy	+44,443	New	+$743K	0.01%	967
2023 Q1	–	Sell	-18,525	Closed	-$411K	–	1535
2022 Q4	$411K	Sell	18,525 -6,593	-26%	-$102K	0.01%	989
2022 Q3	$202K	Sell	25,118 -25,662	-51%	-$232K	0.01%	1186
2022 Q2	$354K	Buy	+50,780	New	+$494K	0.02%	1034

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Trexquant Investment's FDMT Position: Q1 2026 in Review

Trexquant Investment sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 13,229 shares — an estimated $99.2K sold.

Trexquant Investment first reported a position in FDMT in Q2 2022 and held it in 7 quarters. The position peaked at $707K in Q3 2025. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

Trexquant Investment reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
Trexquant Investment sold 13,229 4D Molecular Therapeutics shares in Q1 2026, an estimated $99.2K.
Trexquant Investment first reported a position in 4D Molecular Therapeutics in Q2 2022 and held it in 7 quarters.
Trexquant Investment's 4D Molecular Therapeutics position peaked at $707K in Q3 2025.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.